Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymoctonan SCHEMBL15532000 | 1.00 | REN (0.52) | RENCALCRLRAMP1OPRK1OPRD1 | |
| SCHEMBL30259604 | 0.97 | REN (0.53) | RENCALCRLRAMP1OPRK1OPRD1 | |
| SCHEMBL2195454 | 0.93 | OPRD1 (0.55) | RENOPRK1OPRD1F2ACE | |
| SCHEMBL31323239 | 0.93 | CALCRL (0.56) | CALCRLRAMP1OPRD1F2OPRM1 | |
| SCHEMBL17456231 | 0.93 | REN (0.51) | RENCALCRLRAMP1OPRK1OPRD1 | |
| SCHEMBL30011888 | 0.91 | OPRM1 (0.55) | RENOPRK1OPRM1KEAP1 | |
| SCHEMBL30603858 | 0.90 | CALCRL (0.53) | CALCRLRAMP1OPRD1F2KEAP1 | |
| SCHEMBL31694408 | 0.90 | F2 (0.58) | CALCRLRAMP1OPRK1OPRD1F2 | |
| SCHEMBL30469507 | 0.88 | F2 (0.56) | CALCRLRAMP1OPRK1OPRD1F2 | |
| SCHEMBL29666135 | 0.86 | OPRK1 (0.58) | RENOPRK1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| WO-2021069349-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | claimed |
| EP-3804702-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE AGENT, POLYMER AND SURFACTANT | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3804701-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS PORTIONS OF AN ACTIVE SUBSTANCE | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0696202-A1 | PHARMACEUTICAL COMPOSITION CONTAINING THYMOCTONAN AND AZT | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-02-14 | — | — | EP | claimed |
| WO-1995023610-A1 | PHARMACEUTICAL COMPOSITION CONTAINING THYMOCTONAN AND AZT | PHARMACIA S.P.A. (IT) | 1995-09-08 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| WO-1995023610-A1 | PHARMACEUTICAL COMPOSITION CONTAINING THYMOCTONAN AND AZT | PHARMACIA S.P.A. (IT) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995023610-A1 | PHARMACEUTICAL COMPOSITION CONTAINING THYMOCTONAN AND AZT | PHARMACIA S.P.A. (IT) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995001786-A1 | PHARMACEUTICAL COMPOSITIONS FOR HARDLY SOLUBLE ACTIVE SUBSTANCES | CIBA-GEIGY AG (CH) | 1995-01-19 | — | — | WO | disclosed |
| WO-1995001785-A1 | PHARMACEUTICAL COMPOSITIONS FOR HARDLY SOLUBLE ACTIVE SUBSTANCES | SANDOZ LTD. (CH) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | REN 1396/4885CALCRL 1005/4885RAMP1 1416/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | REN 170/4885CALCRL 379/4885RAMP1 881/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | REN 508/4885CALCRL 1299/4885RAMP1 497/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | REN 511/4885CALCRL 1315/4885RAMP1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.